News/ News/ Oncology Heat Bio’s shares ignite on Opdivo combination data in NSCLC Phil Taylor allogeneic, Bristol-Myers Squibb, cell therapy, Heat Biologics, immuno-oncology, Non-small cell lung cancer, Oncology, Opdivo 0 Comment The pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival Share X Heat Bio’s shares ignite on Opdivo combination data in NSCLC https://pharmaphorum.com/news/heat-bios-shares-ignite-on-opdivo-combination-data-in-nsclc/